Global & Disaster Medicine

An FDA panel, comprised of independent medical experts, voted 17 to 0, that the benefits of TPOXX outweigh its risks as Smallpox antiviral therapy.

Siga

“….The U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) funded the advanced development of oral TPOXX in partnership with SIGA. Additionally, under Project Bioshield, BARDA has acquired two million courses of oral TPOXX and such courses have been delivered to the Strategic National Stockpile (SNS)….”

 


Comments are closed.

Categories

Recent Posts

Archives

Admin